Edwards Lifesciences Expects 2025 Sales Of $5.6B-$6B Vs. Consensus Of $5.91B, With Adjusted EPS Of $2.40-$2.50 Versus Consensus Of $2.44, Reaffirms 2024 Constant Currency Sales Growth Guidance Of 8%-10%
Edwards Lifesciences Expects 2025 Sales Of $5.6B-$6B Vs. Consensus Of $5.91B, With Adjusted EPS Of $2.40-$2.50 Versus Consensus Of $2.44, Reaffirms 2024 Constant Currency Sales Growth Guidance Of 8%-10%
爱德华生命科学预计2025年销售额为56亿美元。与59.1亿美元的一致预期相比，销售额为60亿美元，每股收益调整后为2.40-2.50美元，而一致预期为2.44美元，重申2024年的恒定汇率销售增长指导为8%-10%。
$4.1 - $4.4 billion2025 Guidance
2025 年指南
| Sales |
$5.6 - $6.0 billion (8% - 10% constant currency growth) |
| TAVR |
$4.1 - $4.4 billion (5% - 7% constant currency growth) |
| TMTT |
$500 - $530 million (50% - 60% constant currency growth) |
| Surgical |
$970 million - $1.05 billion (mid-single digit constant currency growth) |
| FX Impact on Sales |
~$100 million unfavorable (~2pt downside to reported growth) |
| Adjusted Gross Profit Margin | 78% - 79% |
| Adjusted Operating Margin | 27% - 28% |
| Tax Rate | 15% - 18% |
| Adjusted EPS | $2.40 - $2.50 |
| Diluted Shares Outstanding | 585 – 595 million |
| 销售 |
56-60 亿美元 （8%-10% 的恒定货币增长） |
| TAVR |
41-44 亿美元 （5%-7% 的恒定货币增长） |
| TMTT |
500-5.3 亿美元 （50%-60% 的恒定货币增长） |
| 外科 |
9.7亿美元至10.5亿美元 （中等个位数的恒定货币增长） |
| 外汇对销售的影响 |
~1亿美元不利 （与报告的增长相比下降了约2个百分点） |
| 调整后的毛利率 | 78%-79% |
| 调整后的营业利润率 | 27%-28% |
| 税率 | 15%-18% |
| 调整后的EPS | 2.40-2.50 美元 |
| 摊薄后的已发行股份 | 585 — 59500万 |
- Increasing contribution from an expanding set of structural heart therapies in 2026 and beyond; targeting 10% average annual total company sales growth and double-digit EPS growth
- Mid-to-high single digit TAVR growth driven by EARLY TAVR and PROGRESS
- TMTT increasing contribution to growth, reaching $2 billion by 2030
- Increasing contribution from new therapeutic areas including Structural Heart Failure and AR
- 在2026年及以后，不断扩大的结构性心脏疗法的贡献将增加；目标是公司年均销售总额增长10％，每股收益增长两位数
- 受早期TAVR和PROGRESS的推动，中到较高的个位数TAVR增长
- tMTT 增加对增长的贡献，到 2030 年将达到 20 亿美元
- 包括结构性心力衰竭和增强现实在内的新治疗领域的贡献越来越大
资讯热榜
更新时间